Personalis, Inc.

🎉 Just 7 days to go! 🎉 BLOODPAC’s third quarter meeting is right around the corner! Join us in just one week on September 4th and 5th in Fremont, California, hosted by @PersonalisInc. We’re so excited to see everyone there! 🚀 #BLOODPACQ3 #OneWeekOut

We’re excited to be at World CB & CDx next week in Boston! Visit us at booth # 25 to learn more about our flagship ultra-sensitive minimal residual disease (MRD) platform, NeXT Personal®. Make sure to check out a presentation by Travis Yates, PhD, Senior Field Applications Scientist, at Personalis. Dr. Yates will cover several impactful studies utilizing NeXT Personal in early-stage lung and breast cancer and explore the implications of using an ultra-sensitive MRD detection assay in these indications. #PrecisionOncology #Biomarkers #LiquidBiopsy #MRD #ctDNA #WorldCDx

📢 ClearNote Health will be at the 14th World CB & CDx Boston Summit from September 3rd to 6th. 📍 Find us at #Booth35 and learn more about the advantages of the Virtuoso Epigenomics Platform, our liquid based monitoring tools and the power of longitudinal analysis in your translational research program. Virtuoso empowers more efficient and effective drug development by providing insights into disease biology, therapy response, and resistance - all from a simple blood draw. Reach out to schedule a meeting in advance! #CDx #drugdevelopment #therapyresponse

ICYMI: Earlier this month, we announced the expansion of our commercial relationship with Tempus AI. Tempus is the exclusive commercial partner for Personalis’ ultra-sensitive tumor-informed minimal residual disease (MRD) product for breast and lung cancers, and for immunotherapy monitoring across all solid tumors. Following exceptionally strong demand, both companies have agreed to accelerate commercialization efforts, including Tempus investing a total of approximately $36 million into Personalis among other key terms. Learn more from the GenomeWeb article: https://bit.ly/3X8GqV4 #PrecisionOncology #LiquidBiopsy #LungCancer #BreastCancer #Immunotherapy #MRDTesting

BLOODPAC's Q3 Meeting is fast approaching, and Personalis is honored to be hosting, as we bring together industry leaders to accelerate the development, validation and accessibility of liquid biopsy assays to improve the outcomes of patients with cancer. Join us in Silicon Valley for two days of innovation and collaboration. #LiquidBiopsy #PrecisionOncology

“Highly sensitive MRD tests like NeXT Personal® will open up even more opportunities to use MRD testing in a broader set of cancer types and stages,” says Dr. Richard Chen, Chief Medical Officer and EVP of R&D at Personalis in this article for Biocompare. Ultra-sensitivity is required from next-generation sequencing based minimal residual disease (MRD) tests to detect cancer recurrence early. Ultra-sensitivity has the power to deliver more trust in the negative MRD result. NeXT Personal is an ultra-sensitive and specific MRD test, which has been shown to detect early-stage lung and breast cancer recurrence months prior to disease being visible on scans. Discover more from the article: https://bit.ly/3yJdivi. #PrecisionOncology #LiquidBiopsy #NGS #MRD #ctDNA

Today, Personalis announced the expansion of our commercial relationship with Tempus AI. Tempus is serving as exclusive commercial partner for Personalis’ ultra-sensitive tumor-informed MRD product for broad patient adoption in breast and lung cancers, and for immunotherapy monitoring across all solid tumors. Following positive reaction and exceptionally strong demand, the companies have agreed to accelerate their efforts, expanding under the following key terms: - Tempus to accelerate its commercialization efforts over the first two years - Personalis to increase the quantity of patient samples it will accept over the corresponding period - Tempus to invest approximately $36 million into Personalis Learn more from the press release: https://bit.ly/3X558H0. #PrecisionOncology #LiquidBiopsy #LungCancer #BreastCancer #Immunotherapy

At Personalis, we’re committed to fostering a diverse and inclusive workplace, and empowering all voices to be heard and seen. Last month, as part of our Diversity, Equity and Inclusion (DEI) initiative we held a Women’s Leadership Panel in which 3 leaders from our team talked about their journeys in the workplace. Thank you to our participants, Deepshikha Bhandari, Janet Lai, and Erin Ayash for sharing their diverse thoughts, perspectives, and approaches to leadership in the workplace. And Gail Stanley for leading this wonderful event! Here are some of the stories and advice that they shared: Erin on comparing leadership to sports: “I played sports through high school, and so I think of it as sort of the coach and the team captain. And I would describe myself more as a team captain. I definitely feel like I'm part of the team. We're all in this together. I'm doing the work, too. I see my role as helping whoever's on my team do their job...I assume that people are here to do a good job, that they want to be here. I'm not going to micromanage or tell you what to do. I'm just going to support you in your efforts.” Janet on describing her leadership style: “I would describe my leadership style as more servant leadership. My parents actually had a textile manufacturing business in Hong Kong, and my dad was the technical person, and my mom did all the business and all the HR and everything. I watched her growing up and she's really, I think, [an] exemplar of servant leadership. She really cares about her employees. She really takes time to listen to get consensus. And as I journey through my role as a manager and as a leader, I think I really take to heart that you cannot force people to follow you. You really have to listen, show empathy and have strong integrity and also have a growth mindset that you can learn from anybody as a leader, doesn't mean you have all the answers.” Deepshikha on having the courage to speak up: “What I try to do a lot is be a role model. I try to walk the talk. And I really believe that irrespective of where you sit, you need to be able to roll up your sleeves to get the job done and drive for results. I'm also a risk taker, and I also believe that a key part of leadership is also having the courage to speak up, and I'm not afraid of being the only person in the room with a certain opinion. The other important aspect of leadership…is also empowerment. You know, it's very important to firstly be authentic in your caring for people, because eventually, people can tell. And so you have to be authentic, and you have to empower people and…have decisions made at the appropriate level.” #WomeninLeadership

We’re honored to be hosting BLOODPAC’s Q3 meeting this upcoming September at our Fremont headquarters! We look forward to a week of wonderful discussion and collaboration with fellow members. #LiquidBiopsy #PrecisionOncology

🎉 Let the countdown begin! 🎉 Just 30 days until BLOODPAC’s in-person third quarter meeting! Join us on September 4th and 5th in Fremont, California, hosted by Personalis, Inc. We can't wait to see everyone there! 🚀 #BLOODPACQ3 #Countdown